Sandoz Group (SDZ) Aandelenoverzicht
Sandoz Group AG ontwikkelt, produceert en verkoopt wereldwijd generieke geneesmiddelen en biosimilars. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 3/6 |
| Toekomstige groei | 3/6 |
| Prestaties in het verleden | 2/6 |
| Financiële gezondheid | 6/6 |
| Dividenden | 0/6 |
Beloningen
Risicoanalyse
Geen risico's gedetecteerd voor SDZ uit onze risicocontroles.
SDZ Community Fair Values
Create NarrativeSee what 54 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Sandoz Group AG Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | CHF 68.78 |
| 52 Week Hoogtepunt | CHF 72.70 |
| 52 Week Laag | CHF 42.01 |
| Bèta | 0.53 |
| 1 maand verandering | 5.82% |
| 3 maanden verandering | 12.39% |
| 1 Jaar Verandering | 58.48% |
| 3 jaar verandering | n/a |
| 5 jaar verandering | n/a |
| Verandering sinds IPO | 182.46% |
Recent nieuws en updates
Narratiefupdate • Jun 11
SDZ: Elevated Biosimilar Ambitions Will Face Tighter Execution And Margin Scrutiny
Analysts have lifted their CHF price target on Sandoz Group to reflect a fair value shift from about CHF 45.23 to roughly CHF 47.30, citing updated assumptions on revenue growth, margins, and future P/E expectations shaped by recent upgrades, downgrades, and target changes across the Street. Analyst Commentary Recent Street research on Sandoz Group has been mixed, with some firms expressing confidence through upgrades and higher price targets, while others are more cautious.
Narratiefupdate • May 28
SDZ: Mixed Rating Shifts And Biosimilar Expansion Will Shape Future P/E
Analysts have adjusted the Sandoz Group price target slightly higher, with the updated fair value estimate moving from about CHF 66.01 to CHF 66.36 as they factor in modestly different assumptions for growth, margins and future P/E, following a mix of recent upgrades, initiations and target changes across the Street. Analyst Commentary Recent research on Sandoz Group reflects a mix of optimism and caution, with several firms adjusting ratings and price targets in different directions.Narratiefupdate • May 01
SDZ: Mixed Rating Shifts And Biosimilar Deals Will Shape Future P/E
The updated analyst price target for Sandoz Group has been revised by approximately CHF 1 higher, reflecting modestly adjusted assumptions around fair value, revenue growth, profit margins and future P/E as analysts balance recent target changes and rating shifts across major banks. Analyst Commentary Recent Street research around Sandoz Group shows a mix of optimism on the company’s long term potential and caution on how current pricing and expectations line up with execution risks.Narratiefupdate • Apr 16
SDZ: Elevated Expectations Will Test Execution On Biosimilar Expansion Plans
Analysts have raised the Sandoz Group price target by roughly CHF 2 per share, reflecting a higher assumed fair value. This is supported by a series of recent CHF 3 to CHF 9 target increases from major banks and generally constructive views, despite some rating downgrades.Recent updates
Narratiefupdate • Jun 11
SDZ: Elevated Biosimilar Ambitions Will Face Tighter Execution And Margin Scrutiny
Analysts have lifted their CHF price target on Sandoz Group to reflect a fair value shift from about CHF 45.23 to roughly CHF 47.30, citing updated assumptions on revenue growth, margins, and future P/E expectations shaped by recent upgrades, downgrades, and target changes across the Street. Analyst Commentary Recent Street research on Sandoz Group has been mixed, with some firms expressing confidence through upgrades and higher price targets, while others are more cautious.Narratiefupdate • May 28
SDZ: Mixed Rating Shifts And Biosimilar Expansion Will Shape Future P/E
Analysts have adjusted the Sandoz Group price target slightly higher, with the updated fair value estimate moving from about CHF 66.01 to CHF 66.36 as they factor in modestly different assumptions for growth, margins and future P/E, following a mix of recent upgrades, initiations and target changes across the Street. Analyst Commentary Recent research on Sandoz Group reflects a mix of optimism and caution, with several firms adjusting ratings and price targets in different directions.Narratiefupdate • May 01
SDZ: Mixed Rating Shifts And Biosimilar Deals Will Shape Future P/E
The updated analyst price target for Sandoz Group has been revised by approximately CHF 1 higher, reflecting modestly adjusted assumptions around fair value, revenue growth, profit margins and future P/E as analysts balance recent target changes and rating shifts across major banks. Analyst Commentary Recent Street research around Sandoz Group shows a mix of optimism on the company’s long term potential and caution on how current pricing and expectations line up with execution risks.Narratiefupdate • Apr 16
SDZ: Elevated Expectations Will Test Execution On Biosimilar Expansion Plans
Analysts have raised the Sandoz Group price target by roughly CHF 2 per share, reflecting a higher assumed fair value. This is supported by a series of recent CHF 3 to CHF 9 target increases from major banks and generally constructive views, despite some rating downgrades.
Narratiefupdate • Apr 01
SDZ: Future P/E Repricing And Biosimilar Expansion May Drive Re Rating
Analysts have lifted the price target for Sandoz Group from CHF 60.37 to CHF 81.99, citing recent initiations, upgrades and target increases that highlight a higher assumed future P/E multiple and slightly improved profit margin expectations, despite more measured revenue growth assumptions. Analyst Commentary Recent Street research on Sandoz Group presents a mixed picture, but there is a clear strand of optimism around execution, earnings quality and the scope for the shares to support higher valuation multiples.Narratiefupdate • Mar 18
SDZ: Mixed Rating Shifts And Biosimilar Expansion Will Shape Future P/E
Analysts have lifted the Fair Value estimate for Sandoz Group from CHF 62.57 to CHF 65.45. This reflects a series of higher Street price targets around CHF 62 to CHF 75 and updated assumptions for modestly higher revenue growth, a slightly lower profit margin profile, and a higher future P/E multiple.Narratiefupdate • Mar 04
SDZ: Mixed Rating Shifts And Biosimilar Pipeline Progress Will Shape Future P/E
Analysts have lifted their fair value estimate for Sandoz to about CHF 63, reflecting updated assumptions for slightly lower revenue growth, a higher profit margin and a modestly lower future P/E, along with recent mixed rating changes and higher price targets in the CHF 70 to CHF 75 range. Analyst Commentary Recent Street research on Sandoz shows a mix of optimism and caution, with price targets now clustering in the CHF 70 to CHF 75 range and ratings shifting closer to neutral.Narratiefupdate • Feb 18
SDZ: Richer Future P/E Assumptions Will Test Biosimilar Execution Confidence
Our latest narrative update on Sandoz Group reflects a higher implied fair value of CHF 58.42, up from CHF 52.75, supported by recent analyst price target increases and a willingness to assign a richer future P/E multiple. Analyst Commentary Recent Street research around Sandoz Group has centered on a series of price target revisions and at least one rating upgrade, which together frame how the analyst community is thinking about valuation, execution risk, and growth potential.Narratiefupdate • Feb 03
SDZ: Elevated Expectations Will Confront Ongoing Execution And Manufacturing Setbacks
Analysts have raised their average price target on Sandoz Group by CHF 3 to CHF 60, citing updated assumptions for revenue growth, profit margins and future P/E, in line with recent target increases from several major banks. Analyst Commentary Recent Street research on Sandoz Group has largely focused on recalibrating price targets to reflect updated views on revenue growth, profitability and valuation multiples.Narratiefupdate • Jan 20
SDZ: Rising Biosimilar Pipeline Will Face Ongoing Execution And Manufacturing Risks
Narrative Update The updated analyst price target for Sandoz Group reflects a modestly lower fair value estimate alongside slightly higher revenue growth and profit margin assumptions. Recent Street research citing price target moves to CHF 60 and CHF 70 indicates that analysts see room for the shares to better reflect these revised expectations.Narratiefupdate • Jan 06
SDZ: Elevated Biosimilar Ambitions Will Face Ongoing Execution And Manufacturing Risks
Analysts have lifted their average price targets on Sandoz Group into a CHF 49 to CHF 70 range, and our updated fair value of CHF 44.42 nudges slightly lower as higher assumed profit margins and revenue growth are offset by a reduced future P/E multiple. Analyst Commentary Recent Street research on Sandoz Group shows a cluster of higher price targets, with targets in the CHF 49 to CHF 70 range.Narratiefupdate • Dec 21
SDZ: Elevated Expectations Will Face Execution Risks In Biosimilars Expansion
Sandoz Group's analyst price target has been lifted by roughly CHF 6.50 to around CHF 60, as analysts now factor in stronger revenue growth, modestly higher profit margins, and a richer forward valuation multiple. Analyst Commentary Recent Street research has been broadly constructive on Sandoz Group, with several major firms lifting their price targets into the CHF 49 to CHF 60 range and maintaining positive ratings.Narratiefupdate • Dec 07
SDZ: Biosimilar Launch Execution Will Shape Future Multiple And Risk Balance
Sandoz Group’s analyst price target has been nudged higher, with fair value estimates rising by about CHF 1.10 to CHF 52.75 as analysts point to sustained revenue growth expectations and a modestly higher future P E multiple, despite slightly lower margin forecasts. Analyst Commentary Bullish analysts have recently raised their price targets into the CHF 55 to CHF 60 range, signaling growing confidence that Sandoz can sustain above market growth and support a higher valuation multiple.Narratiefupdate • Nov 23
SDZ: Sustained Revenue Momentum And Margin Focus Will Shape Fair Value Ahead
The analyst consensus price target for Sandoz Group has increased to CHF 60 from CHF 55. Analysts cite improved margin outlook and sustained revenue growth as key factors supporting the upward revision.Narratiefupdate • Nov 09
SDZ: Recent US Launch and European Expansion Will Influence Near-Term Performance
The average analyst price target for Sandoz Group has increased from CHF 50.33 to CHF 52.05, reflecting improved revenue growth forecasts and recent supportive analyst research updates. Analyst Commentary Recent analyst updates reflect a mix of optimism and caution regarding Sandoz Group's valuation, growth prospects, and execution.Narratiefupdate • Oct 26
Future Opportunities Will Be Unlocked Through Expanding Pipeline And Global Market Reach
The analyst consensus price target for Sandoz Group rose modestly, increasing from CHF 50.20 to CHF 50.33. Analysts cited stronger revenue growth and improving profit margins in their updated outlooks.Narratiefupdate • Oct 12
Biosimilar Pipeline And Global Expansion Will Unlock Future Opportunities
The analyst price target for Sandoz Group has increased by CHF 0.81. This reflects positive sentiment from analysts who cite strong revenue growth and continued profitability improvements as supporting factors.Nieuw narratief • Aug 17
Biosimilar Pipeline And Global Expansion Will Unlock Future Opportunities
Key Takeaways Accelerated biosimilar launches, improved manufacturing, and strong market share are driving margin expansion and long-term profitability. Strategic focus on international growth and a robust product pipeline positions the company for sustainable earnings momentum.Analyseartikel • Jun 25
Sentiment Still Eluding Sandoz Group AG (VTX:SDZ)
You may think that with a price-to-sales (or "P/S") ratio of 2.2x Sandoz Group AG ( VTX:SDZ ) is definitely a stock...Rendement voor aandeelhouders
| SDZ | CH Pharmaceuticals | CH Markt | |
|---|---|---|---|
| 7D | 4.2% | 1.7% | 2.5% |
| 1Y | 58.5% | 29.8% | 12.6% |
Rendement versus industrie: SDZ overtrof de Swiss Pharmaceuticals industrie, die het afgelopen jaar een rendement 29.8 % opleverde.
Rendement versus markt: SDZ overtrof de Swiss markt, die het afgelopen jaar een rendement opleverde van 12.6 %.
Prijsvolatiliteit
| SDZ volatility | |
|---|---|
| SDZ Average Weekly Movement | 4.0% |
| Pharmaceuticals Industry Average Movement | 5.2% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in CH Market | 7.6% |
| 10% least volatile stocks in CH Market | 2.4% |
Stabiele aandelenkoers: SDZ heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de Swiss markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 4% ) van SDZ is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1886 | 22,356 | Richard Saynor | www.sandoz.com |
Sandoz Group AG ontwikkelt, produceert en verkoopt wereldwijd generieke geneesmiddelen en biosimilars. Het bedrijf richt zich op therapeutische gebieden, waaronder hart- en vaatziekten, het centrale zenuwstelsel, oncologie, infectieziekten, pijn en luchtwegen, diabetes, immunologie, endocrinologie, hematologie en oogheelkunde. Het biedt ook een portfolio van actieve farmaceutische ingrediënten en afgewerkte doseringsvormen.
Sandoz Group AG Samenvatting
| SDZ fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | CHF 29.76b |
| Inkomsten(TTM) | CHF 731.69m |
| Inkomsten(TTM) | CHF 8.93b |
40.7x
Koers/Winstverhouding3.3x
P/S-verhoudingIs SDZ overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| SDZ resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$11.16b |
| Kosten van inkomsten | US$5.86b |
| Brutowinst | US$5.30b |
| Overige uitgaven | US$4.39b |
| Inkomsten | US$914.00m |
Laatst gerapporteerde inkomsten
Dec 31, 2025
Volgende inkomensdatum
Aug 05, 2026
| Winst per aandeel (EPS) | 2.11 |
| Brutomarge | 47.50% |
| Nettowinstmarge | 8.19% |
| Schuld/Eigen Vermogen Verhouding | 56.6% |
Hoe presteerde SDZ op de lange termijn?
Bekijk historische prestaties en vergelijkingDividenden
1.2%
Huidig dividendrendement48%
UitbetalingsratioBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/06/17 09:55 |
| Aandelenkoers aan het einde van de dag | 2026/06/17 00:00 |
| Inkomsten | 2025/12/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Sandoz Group AG wordt gevolgd door 36 analisten. 14 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Emily Field | Barclays |
| James Gordon | Barclays |
| Sidhartha Modi | Barclays |